These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 10368634)

  • 41. Lack of somatic mutations in EGFR tyrosine kinase domain in hepatocellular and nasopharyngeal carcinoma.
    Lee SC; Lim SG; Soo R; Hsieh WS; Guo JY; Putti T; Tao Q; Soong R; Goh BC
    Pharmacogenet Genomics; 2006 Jan; 16(1):73-4. PubMed ID: 16344724
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Identification of surrogate markers for determining drug activity using proteomics.
    McClelland CM; Gullick WJ
    Biochem Soc Trans; 2003 Dec; 31(Pt 6):1488-90. PubMed ID: 14641096
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combination of Epithelial Growth Factor Receptor Blockers and CDK4/6 Inhibitor for Nasopharyngeal Carcinoma Treatment.
    Li HP; Huang CY; Lui KW; Chao YK; Yeh CN; Lee LY; Huang Y; Lin TL; Kuo YC; Huang MY; Lai YR; Yeh YM; Fan HC; Lin AC; Hsieh JC; Chang KP; Lin CY; Wang HM; Chang YS; Hsu CL
    Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34204797
    [TBL] [Abstract][Full Text] [Related]  

  • 44. UC2288 induces cell apoptosis of nasopharyngeal carcinoma cells via inhibiting EGFR/ERK pathway.
    Liang R; Zhu X
    J Cancer; 2021; 12(4):988-995. PubMed ID: 33442398
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhibition of progression of PanIN through antagonizing EGFR.
    He X; Zhang H; Xiao M; Kong Y; Li W; Zhang H
    Tumour Biol; 2015 May; 36(5):3245-9. PubMed ID: 25519686
    [TBL] [Abstract][Full Text] [Related]  

  • 46. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
    Poulikakos PI; Zhang C; Bollag G; Shokat KM; Rosen N
    Nature; 2010 Mar; 464(7287):427-30. PubMed ID: 20179705
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The role of epidermal growth factor receptor in head and neck squamous cell carcinoma.
    Pomerantz RG; Grandis JR
    Curr Oncol Rep; 2003 Mar; 5(2):140-6. PubMed ID: 12583831
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anti-EGFR therapies in nasopharyngeal carcinoma.
    Chen X; Liang R; Zhu X
    Biomed Pharmacother; 2020 Nov; 131():110649. PubMed ID: 32836074
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Novel systemic therapeutic for nasopharyngeal carcinoma.
    Chan SL; Ma BB
    Expert Opin Ther Targets; 2012 Mar; 16 Suppl 1():S63-8. PubMed ID: 22313344
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.
    Rewcastle GW; Murray DK; Elliott WL; Fry DW; Howard CT; Nelson JM; Roberts BJ; Vincent PW; Showalter HD; Winters RT; Denny WA
    J Med Chem; 1998 Feb; 41(5):742-51. PubMed ID: 9513602
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tyrosine kinase inhibitors. 13. Structure-activity relationships for soluble 7-substituted 4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.
    Thompson AM; Murray DK; Elliott WL; Fry DW; Nelson JA; Showalter HD; Roberts BJ; Vincent PW; Denny WA
    J Med Chem; 1997 Nov; 40(24):3915-25. PubMed ID: 9397172
    [TBL] [Abstract][Full Text] [Related]  

  • 52. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In vivo toxicity, pharmacokinetics, and anticancer activity of Genistein linked to recombinant human epidermal growth factor.
    Uckun FM; Narla RK; Zeren T; Yanishevski Y; Myers DE; Waurzyniak B; Ek O; Schneider E; Messinger Y; Chelstrom LM; Gunther R; Evans W
    Clin Cancer Res; 1998 May; 4(5):1125-34. PubMed ID: 9607569
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Blockade of the epidermal growth factor receptor tyrosine kinase activity by quercetin and luteolin leads to growth inhibition and apoptosis of pancreatic tumor cells.
    Lee LT; Huang YT; Hwang JJ; Lee PP; Ke FC; Nair MP; Kanadaswam C; Lee MT
    Anticancer Res; 2002; 22(3):1615-27. PubMed ID: 12168845
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Growth inhibition of nasopharyngeal carcinoma cells by EGF receptor tyrosine kinase inhibitors.
    Sun Y; Fry DW; Vincent P; Nelson JM; Elliott W; Leopold WR
    Anticancer Res; 1999; 19(2A):919-24. PubMed ID: 10368634
    [TBL] [Abstract][Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.